人乳头瘤病毒疫苗
医学
dna疫苗
病毒学
接种疫苗
中和抗体
免疫学
免疫
抗体
病毒
HPV感染
宫颈癌
免疫系统
免疫
癌症
内科学
作者
Zahra Yousefi,Hamid Aria,Farhoodeh Ghaedrahmati,Tahereh Bakhtiari,Mahdieh Azizi,Reza Bastan,Rozita Hosseini,Nahid Eskandari
标识
DOI:10.3389/fimmu.2021.805695
摘要
Human papillomavirus (HPV) is the most common sexually transmitted agent worldwide. Early prevention with HPV vaccination is a safe and effective method against this disease. HPV vaccines provided more protection against several oncogenic HPV strains. Three prophylactic HPV vaccines have been approved to target high-risk HPV types and protect against HPV-related disorders. These existing vaccines are based on the recombinant DNA technology and purified L1 protein that is assembled to form HPV empty shells. The prophylactic vaccines are highly immunogenic and can induce production of specific neutralizing antibodies. However, therapeutic vaccines are different from these prophylactic vaccines. They induced cell-mediated immunity against transformed cells, instead of neutralizing antibodies. The second generation of prophylactic HPV vaccines, made from alternative viral components using cost-effective production strategies, is undergoing clinical evaluation. The purpose of this review is to provide a complete and up-to-date review of the types of HPV vaccines and the efficiency of each of them for readers.
科研通智能强力驱动
Strongly Powered by AbleSci AI